CCR5 and metabolic dysfunction-associated steatotic liver disease: (Anstee et al., 2020) Nonetheless, recent studies also provided evidence on alternative CCR2 and/or CCR5 inhibitors in NAFLD/NASH murine models that may represent more effective alternatives.